CagriSema-treated patients achieved superior weight loss compared with those who received cagrilintide 2.4mg, semaglutide 2.4mg or placebo. Topline data were announced from a phase 3 trial ...

In a phase 3 clinical trial investigating the usefulness of its anti-obesity drug candidate CagriSema, after being injected weekly for 68 weeks, patients lost 22.7% of their weight on average.

disappointing trial results of Novo Nordisk's experimental CagriSema weight loss drug, and more. Elon Musk’s Go-To Cost-Cutter Is Working for DOGE I've been to all 50 states. I'm not in a rush ...

Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema. The results showed that treatment with the ...

On Monday, KeyBanc provided insights into the impact of Novo Nordisk (NYSE:NVO)'s Phase 3 results for its obesity treatment, CagriSema, on the GLP-1 market. The analysis suggests that the potential of ...

Investing.com -- Novo Nordisk (CSE:NOVOb) shares jumped over 9% on Monday, despite the company’s disappointing results for its experimental obesity treatment, CagriSema. This followed the ...

The experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7 percent in a late-stage trial, Reuters quoted Novo Nordisk as saying on Friday ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...